Press release

Valbiotis announces the success of its capital increase of €10.2M, fully dedicated to supporting the commercial expansion of its range of scientifically tested natural healthcare products to prevent cardiometabolic imbalances

• Total demand of nearly €6.2M under the maintenance of preferential subscription rights

• Buoyed by the confidence of its shareholders, its institutional investors and its Chinese partner Xianhua Tao (through Ximen RD PTE Ltd, a company wholly owned by Xianhua Tao and a 51% shareholder alongside Valbiotis in the China-based joint venture), Valbiotis now has the resources to deliver on its strong short-term ambitions in France and internationally

La Rochelle, June 26, 2026 (6:00 PM CET) – Valbiotis (FR0013254851 – ALVAL, PEA/PME eligible), a French laboratory specializing in the design and distribution of scientifically tested natural healthcare products to prevent cardiometabolic imbalances and address everyday health issues, announces the success of its capital increase with shareholders’ pre-emptive subscription rights maintained. This fundraising of €10.2M is intended to finance the acceleration of the Company’s commercial development in France and internationally and support self-financed growth.

Sébastien Peltier, Chairman of the Board of Directors and Co-Founder of Valbiotis, comments: “This successful fundraising further strengthens Valbiotis’ rapid growth trajectory as we expand our commercial network and secure supply for our markets in France, Asia and the Middle East. I sincerely thank all the investors whose strong mobilization made this transaction possible: the institutional investors who secured it upstream; Xianhua Tao, whose personal participation further strengthens the strategic ties between Aika and Valbiotis; and our individual shareholders, whose loyalty and trust we are committed to honoring. We approach this acceleration phase with confidence and the conviction that Valbiotis has all the strengths needed to become a reference player in scientifically tested natural healthcare products.”

OFFERING RESULTS

At the end of the subscription period, total demand on an irreducible, reducible and unrestricted basis amounted to 7,204,512 new shares subscribed at a unit price of €0.86, representing 60.85% of the maximum number of new shares to be subscribed, which was 11,840,000. 

Total demand breaks down as follows:

• 4,265,714 shares requested on an irreducible basis, representing 36.0% of the total amount of the issue.
• 2,811,735 shares requested on a reducible basis, representing 23.7% of the total amount of the issue.
• 127,063 shares requested on an unrestricted basis, representing 1.1% of the total amount of the issue.

These subscription requests on an irreducible, reducible and unrestricted basis were satisfied in full.

It should be noted that the Company had received a subscription commitment for a total amount of €2.0M from Ximen RD PTE Ltd, a company wholly owned by Xianhua Tao and a 51% shareholder alongside Valbiotis in the China-based joint venture.

As subscription requests on an irreducible, reducible and unrestricted basis represented approximately 60.8% of the amount of the issue, that is, €6.2M, a total of 4,635,488 new shares, representing 39.2% of the amount of the issue, were allocated and attributed to the shareholders and investors who had committed to subscribe under the issue guarantee, together the “Guarantors”. These guarantee commitments could be called upon if the number of new shares subscribed at the end of a subscription period does not reach 100% of the maximum amount of the capital increase.

As indicated in the press release announcing the launch of the capital increase, the 4,635,488 new shares allocated to the Guarantors, representing approximately €4.0M and corresponding to an allocation rate of 74.6% of the commitments received from the Guarantors, were distributed among them on a pro rata basis.

Out of the €5,797K in guarantee commitments received by the Company, the final allocations to the Guarantors are as follows, it being specified that the commitment made by Avenir France PME, managed by Talence Patrival, to subscribe under the guarantee for €450K is included in the amount of subscriptions on a reducible basis: 

As a result, the total number of shares allocated under the capital increase is 11,840,000 and the allocation summary is as follows:

(1) Including €450K in respect of the subscription guarantee commitment given by Avenir France, managed by Talence Patrival

REMINDER OF THE USE OF THE OFFERING PROCEEDS

The net proceeds of the issue will amount to approximately €8.9 M and will support the Company’s commercial expansion. The funds raised will be allocated to the following objectives:

• 62% will be allocated to financing customer and inventory working capital requirements, in particular securing the plant supply chain; this expected increase in working capital requirements reflects the need to maintain inventory levels in line with our commercial ambitions in France and internationally.
• 25% will be allocated to strengthening the target sales force network, from 16 to 25 medical promotion officers, to achieve our revenue growth objectives and expand the Brand’s presence in France.
• 13% will be allocated to marketing and communications expenses to support the rollout of the offering.

Given the cash position available at the end of April 2026, the expected acceleration of business in line with the strategic plan already communicated and the financial debt repayment schedule, the Company believes that the net proceeds of the Offering, namely €8.9 M, will provide a cash runway extending beyond the third quarter of 2027, not including any potential non-dilutive financing sources that remain to be determined and negotiated, with the Company maintaining its objective of positive EBITDA for fiscal year 2027

SETTLEMENT-DELIVERY

Settlement-delivery and admission of the new shares to trading on the Euronext Growth Paris market are scheduled for June 30, 2026. The new shares will carry current dividend rights, will be immediately assimilated with the Company’s existing shares and will be traded on the same listing line as those shares under the same ISIN code (FR0013254851 – Ticker: ALVAL).

Following settlement-delivery, the Company’s share capital will amount to €3,553,823.40 and will be divided into 35,538,234 ordinary shares with a par value of €0.10 each.

IMPACT OF THE TRANSACTION ON THE SHAREHOLDING STRUCTURE

To the Company’s knowledge, the breakdown of share capital and voting rights before and after completion of the capital increase is as follows.

Impact of the Offering on the breakdown of share capital  

1. Members of the Board of Directors not acting in concert.
2. Company wholly owned by Xianhua Tao, a 51% shareholder alongside Valbiotis in the China-based joint venture.
3. Shares held in registered form only.